GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 121.05%. A quarter ago, it was expected that this company would post a loss of $0.26 per share when it actually produced a loss of $0.11, delivering a surprise of 57.69%.Over the last four quarters, the ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of WGS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Although there are no personal account positions, SOME STOCKS MENTIONED CAN ALREADY BE PART OF THE PORTFOLIOS OF FAMILY AND ASSOCIATES and reti ...

GeneDx Holdings Corp. (NASDAQ:WGS) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies William Bonello - Craig Hallum Mark Massaro - BTIG Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Good day and thank you for standing by. Welcome to the GeneDx Second Quarter 2024 Ear ...

Company Performance - GENEDX HOLDINGS reported revenues of $70.51 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 19.72% and showing a year-over-year increase from $48.71 million [2] - The company has surpassed consensus revenue estimates three times in the last four quarters [2] - The stock has increased approximately 1125.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.5% [3] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $60.1 million, and for the current fiscal year, it is -$0.92 on revenues of $240.9 million [5] - The estimate revisions trend for GENEDX HOLDINGS is favorable, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [12] Industry Context - The Medical Services industry, to which GENEDX HOLDINGS belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [13] - Co-Diagnostics, Inc., another company in the same industry, is expected to report revenues of $0.4 million for the quarter ended June 2024, reflecting a 100% increase from the previous year [7]

Title of each class Trading Symbol Name of each exchange on which registered Class A common stock, par value $0.0001 per share WGS The Nasdaq Stock Market LLC Warrants to purchase one share of Class A common stock, each at an exercise price of $379.50 per share WGSWW The Nasdaq Stock Market LLC GeneDx Holdings Corp. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 x QUART ...

Exhibit 99.1 1 Reported second quarter 2024 revenue from continuing operations of $68.9M with 77% year-over-year growth of exome and genome test revenue 2 Narrowed second quarter 2024 adjusted net loss to $2.7M GeneDx to host conference call today at 4:30 p.m. ET "Our continued organizational focus on execution fueled our strong second quarter results, giving us confidence to raise full year 2024 revenue guidance to between $255-$265 million and reiterate our expectation to reach profitability in the next s ...

With more than 20 years of experience leading the industry in diagnosing children with rare diseases, including performing more than 80% of clinical exomes in the US today, GeneDx is increasing its focus to a rapidly growing segment of its business. GeneDx has seen an 80% year over year increase of its rapid testing business, and the payor landscape is rapidly evolving, with 11 states now offering Medicaid coverage and an increasing number of commercial payors adopting coverage policies for this critical te ...

-- Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) -- Foundation of Clinical Collaborations to Improve Patient Care With more than 600,000 clinical exomes and genomes sequenced and over 100,000 mitochondrial genomes GeneDx has built one of the largest and most sophisticated proprietary genomic datasets. This industry leading dataset enables GeneDx to deliver more definitive answers and clinically actionable results faster to help ...

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry- leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit genedx.com and connect with us on ...

GeneDx Holdings Corp. (NASDAQ:WGS) Q1 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Mark Massaro - BTIG, LLC Matthew Sykes - Goldman Sachs Matthew Stanton - Jefferies Group LLC Operator Ladies and gentlemen, thank you for standing by, and welcome to the GeneDx First Quarter 2024 Earni ...